[{"_1":2,"_100":-5,"_101":-5},"loaderData",{"_3":4,"_26":27},"root",{"_5":6,"_17":10,"_18":19,"_20":21,"_22":10,"_23":-5,"_24":-5,"_25":10},"user",{"_7":8,"_9":10,"_11":10,"_12":-5,"_13":-5,"_14":15,"_16":-5},"roles",[],"isAuthenticated",false,"isPremium","planName","subscriptionStatus","featureFlags",{},"insightsBudget","isDevelopmentHost","userPreferences",{},"recaptchaSiteKey","6LcvOJcUAAAAAHsB-gPGfGktcRlKpH7OTIU_dMTD","isImpersonating","impersonation","affiliateStatus","isFreedomPortal","routes/v2/article/layout",{"_28":29,"_30":31},"notFound",true,"relatedArticles",[32,76,88],{"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":46,"_47":48,"_49":50,"_51":52,"_53":54,"_55":56,"_57":58,"_59":60,"_61":62,"_63":64,"_65":66,"_67":68,"_69":70,"_71":72,"_73":74,"_75":74},"mediaId",6270057,"mediaKeyId","3039657-0f7287006dbf18079ad32480311242db","parentId",3039657,"title","Alaska task force weighs licensing, training and endorsement options for psychedelic-assisted care","audioSeconds",5156,"startMs",844000,"endMs",6000000,"viewUrl","/Search/View?dp=1&key=3039657-0f7287006dbf18079ad32480311242db&start=844&end=6000","thumbnailUrl","https://assets.pipeline.soar.com/3039657-0f7287006dbf18079ad32480311242db/thumbnail_844000.jpg","articleUrl","/articles/6270057/Alaska/Alaska-task-force-weighs-licensing-training-and-endorsement-options-for-psychedelic-assisted-care","mediaUrl","https://secure.pipeline.soar.com/6270057-a16daed783409cf538992af47db14969/orig.mp4?Expires=1770873725&Signature=ZCbeMH0nojQs1v-MKh5LufcrYoXcHFb7n4Ks50JtCaEueX8BRYS79rvPqksVURHAT9eAwsaSdz3KzCF~wrSsyHZ7wtkigMU22Cvz-~heBzqT8~QbfI94yU0moCPxVQ6mFgnugSPgTVlNfSQ361lFxkMWKBDk1aU2nObRCV3ZhD063ChCnBUBQV8BeNDEqxJUbgVohj2e0Or9Y1qipdr27mskqmvZ5U4Sg9pif48QSIAvWsHlWLzIFpQviEZj6w2nNwVaNlruRgAMqm34CTFWM09sE6TTkoMnziGcHzuj7KC3XFIqCIkbeSpROfI5Nx3rBDO8LQmDaT2Q70Jc9Q6Yww__&Key-Pair-Id=KUT5TJCACFTXG","author","Alaska Legislature","date","2025-04-16T00:00:00Z","article","The Alaska Psychedelic Policy Task Force spent much of its meeting discussing how the state should license and certify clinicians and nonlicensed facilitators if psychedelic medicines become approved and rescheduled.

Task force members debated two principal approaches: allow any provider already authorized to prescribe controlled substances to deliver treatment within their scope of practice, or require an added endorsement that documents specific training. Dr. Lawrence summarized the primary regulatory choice as whether authorization should rest on “scope of practice” or an endorsement tied to extra training. Glenn, a task force member, said the task force should consider pharmacists if pending bills (Senate Bill 137 or House Bill 195) expand pharmacists’ authority to prescribe and administer controlled substances.

Members cited models from other states when discussing requirements. Dr. DeMolina pointed to precedents such as Colorado’s framework and academic programs (Naropa University, the California Institute of Integral Studies and University of California Berkeley) that use roughly 150 contact hours, and to Colorado’s optional 40 hours of supervised practicum and 50 hours of consultation as guardrails. “Colorado requires a minimum of 150 hours,” Dr. DeMolina said, noting that supervised practicum and consultation hours were helpful safeguards. Several members suggested that Alaska could adopt a similar baseline but preserve flexibility if federal guidance (FDA/DEA) sets training standards.

On endorsements versus default prescriptive authority, task force members were split. Glenn offered an “alternative” recommendation that providers gain an extra endorsement added to their license after demonstrating training, similar to permits that dentists obtain to provide sedation. Dr. DeMolina and others urged that some form of additional training be recommended for prescribers, with Dr. DeMolina saying the group should treat the care model as “psychedelic assisted psychotherapy, not psychotherapy assisted psychedelics.” Dr. Lawrence proposed that the task force explicitly recommend training content while recognizing the group could defer to any federal guidance that later emerges.

The draft credential matrix circulated by Dr. DeMolina proposed three tiers: (1) entry-level psychedelic facilitator (nondegreed), (2) certified psychedelic-assisted therapy practitioner (licensed clinicians such as LPC/LCSW/MD with added coursework), and (3) traditional healing practitioners with culturally specific criteria. The facilitator track included examples such as a GED minimum, 150 contact hours of training, 40 hours of supervised practicum and 50 hours of consultation in the Colorado model, while the licensed-practitioner track emphasized 150 contact hours tied to pharmacology, trauma-informed care and integration techniques. Several members said the matrix should be moved to an appendix or presented as an example rather than adopted verbatim until the task force can vet each item in detail.

Members repeatedly noted dependence on federal action: if the FDA approves a medication and the DEA reschedules it, state boards (Medical Board, Board of Nursing, Board of Pharmacy, Controlled Substances Advisory Committee) will have an implementation role. Anna Brawley, staff coordinating the draft, said she would revise language to capture the group’s consensus points and circulate an updated draft for review.

Ending: The task force did not vote on a single, final licensing framework at the meeting. Members instead directed staff to clean up the draft, present the credential matrix as an example or appendix, and circulate a revised draft for public comment and further review.","mediaType","Video","parentTitle","04/16/2025 05:15 PM House PSY","oneSentenceSummary","The Alaska Psychedelic Policy Task Force debated whether clinicians should be allowed to provide psychedelic-assisted treatments under existing prescriptive authority or be required to obtain a new endorsement documenting specific training.","taxTitle","2025 Legislature Alaska, Alaska","taxId",78559,"location","Alaska","headline","","shortSummary",{"_33":77,"_35":36,"_37":38,"_39":78,"_41":79,"_43":80,"_45":81,"_47":82,"_49":83,"_51":84,"_53":85,"_55":56,"_57":58,"_59":86,"_61":62,"_63":64,"_65":87,"_67":68,"_69":70,"_71":72,"_73":74,"_75":74},6270047,"Task force sets public-comment timeline, circulates draft and approves meeting formalities",615,6799000,7414000,"/Search/View?dp=1&key=3039657-0f7287006dbf18079ad32480311242db&start=6799&end=7414","https://assets.pipeline.soar.com/3039657-0f7287006dbf18079ad32480311242db/thumbnail_6799000.jpg","/articles/6270047/Alaska/Task-force-sets-public-comment-timeline-circulates-draft-and-approves-meeting-formalities","https://secure.pipeline.soar.com/6270047-e2c192392366c32560a936c5bcaccaba/orig.mp4?Expires=1770873725&Signature=e-Uiy3Z3WydxxAlWDhjbCYz4QWzOCP9dQ6gc5UCj46uxiVNsLSz~Q0Bd6S-aWdWbMpYNfBmCVsXeQLZSX0yCl317nrORsjYyuXdpKny9rE37SxpulMPSLNGj75N24t3wkmHS2-VLdq55eu1dyTxbWrXhGDxy0INxS1ZPxA17EpN16dk5WgnNoUHDVDvpSnbRk1PmQwP6LuiT1eYEhelVDoM6OxgRKnFZk93owK1wEUyo2gZc9umbISc-IRityRgRgU0fhQ2P772krRYNTXj7VpZBFWHiugMQDcevKRcY02habpFWayEyd9qsQifB35uDJxg5wDMXzfSdDvmUpKUttQ__&Key-Pair-Id=KUT5TJCACFTXG","Task force staff outlined a short public-comment schedule and the mechanics for receiving feedback on the draft recommendations.

Anna Brawley said staff would post the draft to the Legislature’s website and run a two-week public-comment period; she stated the window would run “starting Monday, the 20 first, until Monday, May 5,” and said the April 29 meeting would include a public-comment slot for testimony if comments were submitted to be included in the packet by April 28. Staff requested members identify organizations and networks to which they could distribute the flyer and draft. Seth, staff support, said typical public‑testimony timers are two to three minutes per speaker; the task force discussed allowing out‑of‑state commenters but focusing outreach on substantive, technical feedback rather than generic support or opposition.

On routine agenda business, the task force formally approved the meeting agenda (motion moved by Dr. J. Molina; second recorded as Laurie) and approved the previous meeting’s minutes (moved by Anne Ringstead; second Justin Heminger). The meeting adjourned after members voted to close the session.

Ending: Staff will circulate the edited draft report and outreach materials to the full group, collect suggested outreach contacts, and accept written public comments through the stated comment period.","Staff announced a two-week public comment window and a public testimony slot at the April 29 meeting; the task force approved the agenda and previous meeting minutes and adjourned. Staff will circulate the draft report and outreach flyer and asked members to share contacts for outreach.",{"_33":89,"_35":36,"_37":38,"_39":90,"_41":91,"_43":92,"_45":93,"_47":94,"_49":95,"_51":96,"_53":97,"_55":56,"_57":58,"_59":98,"_61":62,"_63":64,"_65":99,"_67":68,"_69":70,"_71":72,"_73":74,"_75":74},6270053,"Task force outlines clinical model and safety recommendations: preparation, supervised medicine sessions and integration",1297,3303000,4600000,"/Search/View?dp=1&key=3039657-0f7287006dbf18079ad32480311242db&start=3303&end=4600","https://assets.pipeline.soar.com/3039657-0f7287006dbf18079ad32480311242db/thumbnail_3303000.jpg","/articles/6270053/Alaska/Task-force-outlines-clinical-model-and-safety-recommendations-preparation-supervised-medicine-sessions-and-integration","https://secure.pipeline.soar.com/6270053-7a00ffb44d2cf3e233491feac8882cd4/orig.mp4?Expires=1770873725&Signature=IffzPyEkd9o36owDOkYGJzoklda9pSX-TmV-Y3bbqXejixE1SYAjyt~6PAdDh0G-lOkMShxW2EOcHLJc9jlQuDmhFslFiDbgITNXXQZ8nxwQdc3fytV27coJTpabVJKuuGOuviz8lHDglQvSlO7Y69V9D5uZnGgby4RM3SKJsF0toXo4~7YPnm9i6Bqkm71SRZL0bLHYJEPOxkkiupuxFXvC5m~R2KNfs2RlhSWgXOPAIdsP~VtxSo9aheRHw~Mse~pD9c4l-a8Y45xyYDwlW9RAp2oTzuTQ7GikeVmybyjUQso0-LB8koKQ71Ary6aus9tqVb46VHp~NEn2E2TwmA__&Key-Pair-Id=KUT5TJCACFTXG","Members of the Alaska Psychedelic Policy Task Force described a clinical model and a set of best practices they consider important for patient safety if psychedelic medicines become medically available.

Dr. DeMolina summarized a three-part model used in trials and contemporary practice: preparation sessions, supervised medicine sessions in a controlled setting, and post‑session integration therapy. “It’s psychedelic assisted psychotherapy, not psychotherapy assisted psychedelics,” Dr. DeMolina said, arguing the therapy component is central to outcomes reported in phase‑3 trials.

The task force discussed concrete elements of that model: multiple preparation sessions (one to three depending on medication), an informed consent process with detailed safety planning, medical and clinical evaluation to rule out exclusionary conditions (cardiac risks, bipolar disorder considerations), and mandatory integration sessions. Dr. Lindquist recommended wording in the draft change “psychological evaluation” to “medical and clinical evaluation” to better reflect the range of assessment tools clinicians may use; the task force agreed to revise language accordingly.

On sitters and facilitators, members debated whether two-person teams should be required for medicine sessions, as in some MAPS protocols, and whether nonlicensed facilitators could operate independently. Dr. DeMolina described the practical benefits of two clinicians during long sessions but noted insurance and CPT‑coding limits for multi‑hour, two‑person staffing. Several members supported ongoing clinical supervision for nonlicensed facilitators and attachment to a certified clinic or provider network; Dr. Lindquist said she would expect facilitators to have “ongoing clinical supervision” and not to practice entirely independently.

Cultural and traditional-healer roles were also discussed. Task force members proposed pathways for traditional healing practitioners modeled on existing Alaska Commission on Behavioral Health Certification approaches, while stressing that traditional healers would be part of multidisciplinary teams with patient consent rather than mandatory for every patient. Participants emphasized telehealth and local “boots-on-the-ground” roles (behavioral health aides or trained facilitators) as ways to extend access to remote communities while maintaining safety.

Ending: The task force agreed to convert much of the operational detail into a descriptive section of the draft report that explains current best practices and to label the credential matrix as an example for further development rather than adopting it immediately.","Members recommended that psychedelic-assisted care follow a three-part clinical model (preparation, supervised medicine sessions, integration); emphasized trauma-informed training, cultural responsiveness and limits on unsupervised home use. MAPS ethics and phase‑3 trial approaches were discussed as precedents.","actionData","errors"]

Article not found

Alaska task force weighs licensing, training and endorsement options for psychedelic-assisted care

Task force sets public-comment timeline, circulates draft and approves meeting formalities

Task force outlines clinical model and safety recommendations: preparation, supervised medicine sessions and integration